Clindamycin

• Description :

  Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs) . Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA) . Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) . Clindamycin also can be used for researching malaria[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H301-H311-H331-H341

• Target :

  Antibiotic; Bacterial; Parasite

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/clindamycin.html

• Purity :

  99.90

• Solubility :

  DMSO : 125 mg/mL (ultrasonic) |H2O : 2 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O

• Molecular Formula :

  C18H33ClN2O5S

• Molecular Weight :

  424.98

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361-P403+P233-P405-P501

• References & Citations :

  [7]Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharm. 2007 Mar 6;332 (1-2) :17-23.|[8]Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001 Sep;45 (9) :2638-42. |[1]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17 (1) :38.|[2]Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25 (1) :9-14.|[3]Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother. 1999 Mar;43 (3) :616-22.|[4]Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy. 1987;33 (4) :243-9. |[5]Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg. 2008 Mar;128 (3) :317-23.|[6]Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? Clin Oral Investig. 2021 May;25 (5) :3257-3266.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Plasmodium

• Citation 01 :

  ACS Environ Au. 2025 Aug 8.|ACS Omega. 2022 Mar 3;7 (10) :9004-9014.|Acta Pharm Sin B. 2021 Sep;11 (9) :2850-2858.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Dermatol Clin. 2024 September 12.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|EBioMedicine. 2022 Apr;78:103943.|Future Microbiol. 2025 Oct 13:1-10.|Microbiol Spectr. 2025 Oct 15:e0122125.|Water Res. 2023 Jul 15:240:120110.|bioRxiv. 2024 Jan 18.|bioRxiv. 2024 May 10.

• CAS Number :

  [18323-44-9]